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ABSTRACT
Human DNA topoisomerase I (hTop1p) catalyzes the
relaxation of supercoiled DNA and constitutes the
cellular target of the antitumor drug camptothecin
(CPT). The X-ray crystal structure of the enzyme
covalently joined to DNA and bound to the CPT
analog Topotecan suggests that there are two
classes of mutations that can produce a CPT-
resistant enzyme. The first class includes changes
in residues that directly interact with the drug,
whereas a second class alters interactions with
the DNA and thereby destabilizes the drug binding
site. The Thr729Ala, that is part of a hydrophobic
pocket in the enzyme C-terminal domain, belongs
to a third group of mutations that confer CPT resis-
tance, but do not interact directly with the drug or
the DNA. To understand the contribution of this resi-
due in drug resistance, we have studied the effect
on hTop1p catalysis and CPT sensitivity of four
different substitutions in the Thr729 position
(Thr729Ala, Thr729Glu, Thr729Lys and Thr729Pro).
Tht729Glu and Thr729Lys mutants show severe
CPT resistance and furthermore, Thr729Glu shows
a remarkable defect in DNA binding. We postulate
that the maintenance of the hydrophobic pocket
integrity, where Thr729 is positioned, is crucial for
drug sensitivity and DNA binding.
INTRODUCTION
Human DNA topoisomerase I is a monomeric highly
conserved enzyme composed by 765 amino acids orga-
nized in four mains domains: the N-terminal domain
(residues 1–214), highly disorganized, contains the nuclear
localization signals and is the only region of the protein
not yet crystallized; the core domain (residues 215–635)
that can be divided in three subdomains, subdomain I
(residues 215–232 and 320–433), II (residues 233–319)
and III (residues 434–635); the linker domain (residues
636–712) composed by two protruding coiled coil
a-helices, one of them engages direct contact with
the DNA molecule; the C-terminal domain (residues
713–765) contains the Tyr723 that performs a nucleophilic
attack to the 30phosphate of the DNA, forming a transient
covalent protein–DNA complex that is resolved by a
second transesteriﬁcation mediated by the 50-OH of the
scissile DNA strand (1–3). The topoisomerase I is a bi-
lobed protein that clamps completely around duplex DNA
through protein–DNA phosphate interaction. One lobe is
constituted by the C-terminal catalytic domain and core
subdomain III, the other one (called ‘cap’) by core sub-
domains I and II. Human DNA topoisomerase I has a
medical relevance because it is the natural target of
plant alkaloid camptothecin (CPT) whose derivatives are
frequently used as anticancer drug (4–7). CPT interacts
reversibly with the enzyme blocking the DNA–protein
complex after the cleavage, slowing the religation and
causing severs damages to the DNA. Furthermore, repli-
cationforksprogressioncangeneratedouble-strandbreaks
inducing apoptotic response. A number of mutations that
renders the enzyme resistant to the CPT have been
described (8). Some of them are located near to the active
site and in any case around the CPT binding site or con-
tactingdirectlytheDNAmolecule,fewothermutationsare
located far from the active site (Ala653Pro, Glu418Lys)
(9,10), inﬂuencing the dynamic of the protein–drug inter-
action and modifying the intradomain interactions.
The X-ray crystal structure of human topoisomerase
I covalently joined to double-stranded DNA and bound
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mutations that aﬀect CPT sensitivity (11).
The Thr729Ala mutation has been ﬁrstly identiﬁed to
impart drug resistance on human topoisomerase I in the
CPT-11 (Irinotecan, a CPT analog) resistant human lung
cancer cell line, PC-7/CPT (12) but our data reveal that
the equivalent eﬀect with CPT can not be observed if the
enzyme, harboring the same mutation, is expressed in
the yeast Saccaromyces cerevisiae. Interestingly, looking
at the protein structure, Thr729 seems to be too distant
to contact the drug directly and it is not clear how the
structure or stability of the intercalation drug-binding
pocket is aﬀected by the mutation. The Thr729 resides
in the hydrophobic core of the C-terminal domain
12.4A ˚ from the catalytic tyrosine and 13.1A ˚ from
Asn722 that establishes a water-mediated contact directly
to the drug. Changing the Asn722 to Ser, shortening the
side chain, is suﬃcient to impart CPT resistance to the
protein (13,14). According to these data, Redinbo and
co-authors (15) assumed that the basis of the Thr729
mutants CPT resistance come from the destabilization of
the C-terminal region that could lead to the speciﬁc shift
in position of Asn722, consequentially inducing the break-
age of the water-mediated contact with the drug.
In order to conﬁrm these hypotheses, we analyzed the
eﬀect of Thr729 substitutions to Lys, Pro and Glu on the
in vivo and in vitro catalytic activity and drug sensitivity of
the human DNA topoisomerase I. These three substitu-
tions were chosen for their positive or negative charge, Lys
and Glu, respectively, and for their capability in distorting
the a-helix as in the case of Pro. Our results show that the
729 position is a key point in maintaining the correct
geometry of the hydrophobic pocket of the C-terminal
domain. In fact, even if the enzyme keeps on its catalytic
properties and its sensitivity to CPT in the presence of a
Thr729Ala mutation, a dramatic CPT resistance eﬀect
could be observed when the Thr729 was mutated to Lys
or Glu, and a minor consequence could be seen in the
presence of a Pro. Furthermore, the Thr729Glu mutant
shows a remarkable defect in the DNA binding indicating
that the integrity of the C-terminal geometry is essential
for the preservation of the correct interactions between the
enzyme and its substrate during the progression of the
catalytic cycle. Dynamic simulation experiments described
in the accompanying paper, propose a structural and
dynamical interpretation for the role played by residue
729 in these long-range protein–DNA communications
(Chillemi et al.)
MATERIALS AND METHODS
Yeaststrains and plasmids
Camptothecin (Sigma-Aldrich, Europe) was dissolved in
Me2SO to a ﬁnal concentration of 4mg/ml and stored at
 208C. Anti-FLAG M2 aﬃnity gel, 3xFLAG peptide and
M2monoclonalantibodywerepurchasedfromSigma.Sac-
charomyces cerevisiae strain EKY3 (ura3-52, his3D;200,
leu2D;1, trp1D;63, top1::TRP1, MAT) were previously
described (16,17). Plasmid YCpGAL1-hTOP1 in which
the human topoisomerase I gene is expressed under
the galactose inducible promoter was described pre-
viously (18,19). The htop1Thr729Ala, htop1Thr729Pro,
htop1Thr729Lys and htop1Thr729Glu were generated by
oligonucleotide-directed mutagenesis of the hTop1Y
CpGAL1 (Stratagene, USA-QuickChange XL-Site-
Directed Mutagenesis Kit). All the constructs contain the
N-terminal sequence FLAG which specify for the
DYKDDDY octapeptide, recognized by the M2 monoclo-
nal antibody (20).
Drug sensitivity assay
Yeast EKY3 strains were transformed with YCp50,
YCpGAL1-hTOP1, YCpGAL1-htop1Thr729Ala, YCpG
AL1-htop1Thr729Pro, YCpGAL1-htop1Thr729Lys, YC
pGAL1-htop1Thr729Glu and YCpGAL1-htop1Ala653
Pro-Thr718Ala vectors by LiOAc treatment (21) and
selected on synthetic complete (SC)-uracil medium supple-
mented with 2% dextrose. Transformants were grown to
an A595=0.3 and 5ml aliquots of serial 10-fold dilutions
were spotted onto SC-uracil plates plus 2% dextrose or
2% galactose, with or without the indicated concentra-
tions of CPT.
Purification of DNA topoisomerase I
Epitope-tagged hTop1 proteins were partially puriﬁed
from galactose-induced EKY3 cells transformed with
YCpGAL1-hTOP1, YCpGAL1-htop1Thr729Ala, YCpG
AL1-htop1Thr729Pro, YCpGAL1-htop1Thr729Lys or
YCpGAL1-htop1Thr729Glu by phosphocellulose chro-
matography as previously described (22,23). hTop1 pro-
teins eluted in TEEG [50mM Tris (pH 7.4) 1mM EDTA,
1mM EGTA, 10% glycerol] plus 0.8M KCl were diluted
to a ﬁnal 150mM KCl and applied to an anti-Flag M2
aﬃnity gel column. The column was washed with TBS
[50mM Tris (pH 7.4), 150mM KCl] and the hTop1 pro-
teins were eluted with a solution of 100mg/ml 3xFlag pep-
tide in TBS. The active fractions were dialyzed using a
Spectra/Por Float-A-Lyzer 50000 MWCO to eliminate
the competitor Flag peptide. Proteins were quantiﬁed
using Bradford assay and immunoblot densitometry ana-
lysis. The fractions were adjusted to a ﬁnal concentration
of 40% glycerol and stored at  208C.
hTop1p activity invitro
hTop1p activity was assayed in a DNA relaxation assay
(18,22). Equal concentrations of hTop1 proteins were
incubated in 30ml reactions containing 0.5mg of negatively
supercoiled pHC624 plasmid DNA in 20mM Tris (pH
7.5), 0.1mM Na2EDTA, 10mM MgCl2,5 0 mg/ml acety-
lated BSA and the indicated concentration of KCl.
Reactions were incubated at 378C and terminated with a
ﬁnal concentration of 0.5% SDS. Two sets of time course
relaxation experiments were conducted. In the ﬁrst set, the
assay was performed with an excess of DNA, 400fmol,
relative to an enzyme concentration of 130fmol, (DNA/
enzyme ratio 3:1). The second set contained an excess of
enzyme, 1200fmol, compared to DNA (DNA/enzyme
ratio 1:3). Both the experiments were performed in the
presence of KCl 150mM and 378C of temperature for
the indicated time and stopped by addition of SDS with
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ucts were resolved in 1% agarose gels, stained with
ethidium bromide and visualized with a BioRad Gel
doc system.
To quantify relative levels of supercoiled and relaxed
DNA topoisomers, the stained gels were ﬁrst exposed to
UV light to induce photo-nicking of the DNA, then
restained with ethidium bromide. These steps obviated
any contribution of DNA topology to ethidium bromide
binding and consequently, relative band intensity.
DNA cleavage assays
CPT-induced stabilization of hTop1-DNA covalent com-
plexes was assessed in DNA cleavage assays as described
(16,22,23). Brieﬂy, equal concentrations or equal activi-
ties of puriﬁed hTop1 proteins were incubated in 50ml
reactions with a single 30 32P-end-labeled 900-bp DNA
fragment, which contains a high aﬃnity hTop1p cleavage
site (25) and was excised from plasmid pBlueAK3–1 (23).
Where indicated, reactions were supplemented with 10mM
CPT. Me2SO was added to the no drug controls.
Following incubation at 378C for 30min, reactions were
terminated by the addition of 1% SDS and the cleavage
products were resolved in a 7M urea/8% polyacrylamide
gel and visualized by Phosphorimager analysis (26).
Kinetics ofreligation using oligonucleotide substrate
To assess enzyme catalyzed DNA cleavage and religation,
a truncated suicide oligonucleotide substrate was used.
A 14-nt oligo CL14 (50-GAAAAAAGACTTAG-30),
which contains a hTop1p high aﬃnity cleavage site, was
50-end-labeled with [g
32P] ATP and T4 polynucleotide
kinase. A 25-nt CP25 (50-TAAAAATTTTTCTAAGTC
TTTTTTC-30) complementary strand, which was
50phosphorylated with unlabeled ATP and a 11-nt R11
(50-AGAAAAATTTT-30) religation oligonucleotide. The
three strands were annealed at a molar ratio of 2:3:1 of
CP25: CL14: R11 in 100mM NaCl, 1mM EDTA and
1mM DTT by heating to 958C for 5min, followed by
slow cooling to room temperature. The resulting DNA
substrate (20nM) was incubated with equal concentra-
tions of hTop1 proteins in 20mM Tris (pH 7.5), 0.1mM
EDTA, 10mM MgCl2, 50mg/ml acetylated BSA and
150mM KCl at 378C. At the times indicated, 5ml aliquots
were quenched with 0.5% SDS and heating to 758C. The
reaction products were trypsinized and resolved in 7M
urea/20% acrylamide gels. The percentage of religation
was determined by PhosphorImager and ImageQuant
software and normalized on the total amount of radio-
activity in each lane.
DNA-binding assay
To assess enzyme DNA binding a 100-nt DNA oligonu-
cleotide (50-GCTATCGAATTCGCTATAATTCATATG
ATAGCGGATCCAAAAAAGACTTAGAAAAAAAA
AAAGCTTAAGCAACATATGGTATCCGGAATTCA
AT-30) containing the Tetrahimena termoﬁla high aﬃnity
DNA topoisomerase I binding site was 50-end-labeled with
[g
32P] ATP and T4 polynucleotide kinase. The complemen-
tary strand was 50 phosphorylated with unlabeled ATP.
The two strands were annealed at a molar ratio of 1:1 in
100mM NaCl, 1mM EDTA and 1mM DTT by heating to
958C for 5min, followed by slow cooling to room tempera-
ture. DNA binding of hTop1 was assayed by nitrocellulose
ﬁlter binding as previously described (24,27). Brieﬂy,
hTop1 and mutant proteins (0–5pmol) were incubated
in 100ml of binding buﬀer [20mM Tris (pH 7.5),
10mM MgCl2, 0.1mM EDTA, 50mg/ml gelatin and
1mM b-mercaptoethanol], 150mM KCl, containing
20000c.p.m. (50–100fmol) of 50-end-labeled DNA sub-
strate for 5min at room temperature. Cellulose acetate
microcentrifuge spin columns (Micron Separations Inc.,
USA) with 6-mm diameter nitrocellulose ﬁlter (0.45mm)
were pre-washed with 100ml of salmon sperm solution
100mg/ml to reduce the DNA non-speciﬁc binding, sub-
sequently the samples were applied on the ﬁlter and the
unbound DNA was eluted by centrifugation at 6000
r.p.m. (2800g). After a subsequent washwith100mlofbind-
ing buﬀer 200mM KCl, the amounts of labeled DNA,
eluted and ﬁlter retained, were counted using a Beckman
LS801 liquid scintillation counter.
The percentage of DNA binding was calculated as
(ﬁlter-bound c.p.m.)/(ﬁlter-bound c.p.m.)+(combined
eluent c.p.m.). The obtained data were corrected for the
non-speciﬁc binding of free DNA, which was generally
1–2% of the total DNA. Protein-ﬁlter binding was veriﬁed
by immunoblot.
RESULTS
AnalteredCPT sensitivity was shown by Thr729mutants
when expressedin yeast
To assess the in vivo consequences of htop1Thr729 mutant
expression, the viability and CPT sensitivity of top1;
cells transformed with GAL1-top1 constructs were assayed
(Figure 1). The top1; cells expressing human TOP1 exhi-
bit a severe drop in viability in the presence of CPT,
whereas cells expressing Thr729 mutants displayed diﬀer-
ent level of CPT sensitivity.
Thr729Lys and Thr729Glu mutations render the
enzyme clearly resistant to CPT being viable in the pres-
ence of the drug. However, a diﬀerence in the CPT con-
centration that renders the cells able to grow in Gal media
was observed: Thr729Glu mutant produces viable colonies
until 1mg/ml of CPT while Thr729Lys mutant is less resis-
tant, growing in the presence of 0.5mg/ml of drug. Even
though the introduction of a Pro normally disturbs the
a-helix folding, the Thr to Pro substitution does not dra-
matically interfere with the hTop1p sensitivity to CPT.
In fact, cells expressing htopIThr729Pro protein display
only a minor capability to grow in the presence of
0.05mg/ml of CPT. A correlation between the point muta-
tion htopIThr729Ala and the alteration in the sensitivity
to hTopIp inhibitor irinotecan, was previously described
in the CPT11 resistant human lung cancer cell lines, PC-7/
CPT. Nevertheless, our results indicate that the expression
of the same mutation in Saccaromyces cerevisiae does not
show resistance to CPT.
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To assess whether the imposed substitutions in the 729
position could alter the relaxation activity of the
enzyme, the mutants were puriﬁed from galactose-induced
yeast top1 cells, as described in the Materials and meth-
ods section and tested for their speciﬁc activity. Serial
dilutions of equal protein concentrations were incubated
with negatively supercoiled plasmid DNA and the reac-
tion products resolved in agarose gels. As illustrated in
Figure 2, at optimum salt condition for the wild-type
enzyme (i.e. 150mM), the speciﬁc activity of htopI
Thr729Glu was signiﬁcantly reduced, while htop1
Thr729Ala, htop1Thr729Pro and htop1Thr729Lys show
an overall activity quite comparable to that of hTop1p.
The observed reduction of htop1Thr729Glu speciﬁc activ-
ity could result from several alterations in enzyme cataly-
tic cycle, including DNA association, cleavage, strand
rotation and ligation. To discriminate between these pos-
sibilities, we analyzed step by step the catalytic cycle of the
mutants and compared it to that of the wild-type enzyme.
We ﬁrst assessed the eﬀects of ionic strength on mutant
enzyme catalysis. hTop1p activity exhibits a salt optimum
around 150mM. Deviations from this value have pre-
viously been shown to correspond to increased or
decreased DNA binding, for salt optimum more or less
than 150mM, respectively. Limiting amounts of hTop1p
or htop1 mutants were incubated in plasmid relaxation
assays containing increasing concentrations of KCl
(Figure 3A). The percentage of relaxed plasmid DNA
topoisomers produced ([relaxed DNA topoisomers]/
[relaxed+supercoiled DNA topoisomers]) following
incubation with the enzymes was quantiﬁed and
plotted as a function of salt concentration (Figure 3B).
Thr729 mutants display signiﬁcant diﬀerences in their
requirements for optimum of KCl concentration. In fact,
while htopIThr729Ala shows a maximum in the catalytic
activity comparable to that of the wild-type enzyme
(150mM KCl), DNA relaxation catalyzed by htop1
Thr729Pro and htop1Thr729Lys was enhanced at lower
salt concentrations (100mM KCl). The minimum KCl
concentration is shown by the Thr729Glu mutant where
the optimum is reached at 25mM KCl. These results
are consistent with a general lower aﬃnity eﬀect of
htop1Thr729 mutants for DNA than wild-type enzyme
that becomes maximum in the case of the htop1
Thr729Glu protein.
Thr729 mutantsensitivity to CPTin vitro
To assess the mechanism of Thr729 mutant resistance
to CPT, the ability of CPT to stabilize the covalent
DNA–enzyme complex was assessed in a DNA cleavage
assay.
Equal concentrations of hTop1p and mutants proteins
were incubated with a 900-bp 30-end-labeled DNA frag-
ment. Following incubation at 378C for 30min, the cleav-
able complexes were trapped by SDS and the cleaved
DNA fragments were resolved in a denaturing polyacry-
lamide gel, Figure 4. Under these conditions, the relative
intensity and distribution of cleaved DNA fragments can
be used to assess mutation and/or CPT-induced altera-
tions in the steady-state levels of covalent enzyme–DNA
intermediates.
Figure 1. An altered CPT sensitivity was shown by T729 mutants when expressed in yeast. Exponential cultures of EKY3 (top1) cells transformed
with vector control YCp50, YCpGAL1-hTOP1, YCpGAL1-htop1Ala653Pro,Thr718Ala [a known CPT resistant mutant (29)], YCpGAL1-
htop1Thr729Ala, YCpGAL1-htop1Thr729Pro, YCpGAL1-htop1Thr729Lys and YCpGAL1-htop1Thr729Glu were serially 10-fold diluted and
spotted onto SC-uracil plates supplemented with dextrose (Dex) or galactose (Gal) and, as indicated, CPT. Cell viability was assessed following
incubation at 308C.
Figure 2. Thr729 mutants are catalytically active in vitro. A total of 120pmol of puriﬁed hTop1p, hTop1Thr729Ala, hTop1Thr729Pro,
hTop1Thr729Lys and hTop1Thr729Glu were serially 10-fold diluted and incubated in DNA relaxation assays with negatively supercoiled plasmid
DNA. Following incubation at 378C for 30min, the reaction products were resolved in agarose gels and visualized after staining with ethidium
bromide. C indicates no enzyme control.
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cleavage of the labeled DNA strand is detected but when it
is exposed to the drug, a dramatic increase in cleaved
DNA fragments is observed, indicating that CPT stabilize
the covalent enzyme–DNA intermediate. The same result
is observed in the case of htop1Thr729Ala showing that
this mutant is not resistant to CPT in vitro. A diﬀerent
behavior is observed with htop1Thr729Glu, htop1Thr
729Pro and htop1Thr729Lys mutants. The htop1T729
Glu does not trap any signiﬁcant covalent DNA–enzyme
intermediate, while cleavage occurs in the presence of
CPT for the htop1Thr729Pro and htop1Thr729Lys,
providing a direct evidence for drug binding to the
mutant–DNA complexes. The extent of cleavage correlate
with the in vivo drug resistance of the two mutants, show-
ing a reduction of cleavable complex formation that is
most evident in the case of htop1Thr729Lys.
The same eﬀect can be detected using equal activity of
proteins (Supplementary Figure 4S).
Taking together these data strongly conﬁrm the diﬀer-
ential drug resistance produced by the htop1Thr729
mutants in the in vivo assays and suggest that the
Thr729 could have a key role in maintaining the correct
geometry during the protein binding with the drug. To
address such dynamic interactions, we used an oligonu-
cleotide-based DNA substrate to uncouple hTop1p cata-
lyzed DNA cleavage from religation.
Analysisof thereligation rate using asuicide substrate
A common strategy to uncouple DNA cleavage from reli-
gation is to use an oligonucleotide-based substrate that
contains a truncated scissile strand. For example, as
depicted in Figure 5A, hTop1p cleavage of a high
aﬃnity site within a suicide DNA substrate liberates a
dinucleotide and traps the covalent hTop1p–DNA
complexes. In the presence of hTop1p, religate DNA
Figure 3. The htop1Thr729Glu and htop1Thr729Lys mutant enzymes
exhibit a lower salt optimum than wild-type hTop1p in plasmid DNA
relaxation assays. (A) Limiting amounts of puriﬁed hTop1p, htop
1Thr729Ala, htop1Thr729Pro, htop1Thr729Lys or htop1Thr729Glu
were serially 10-fold diluted and incubated with plasmid DNA at
378C, in the presence of the indicated concentration of KCl. The reac-
tion products were resolved in agarose gels as described in Figure 2. (B)
The percentage of relaxed plasmid DNA topoisomers obtained with
hTop1p (ﬁlled square), htop1Thr729Ala (inverted ﬁlled triangle),
htop1Thr729Pro (ﬁlled triangle), htop1Thr729Lys (open circle) and
htop1The729Glu (open diamond) at the indicated concentration of
KCl were determined in a minimum of three independent assays.
Error bars indicate SDs from the mean.
Figure 4. Cleavage–religation equilibrium. Equal concentrations of
hTop1p, htop1Thr729Al, htop1Thr729Pro, htop1Thr729Lys or
htop1Thr729Glu were incubated with a single
32P-end-labeled DNA
fragment in absence or presence of CPT as described in Materials
and methods section. After 30min the reactions were stopped with
0.5% SDS and the cleavage products resolved by urea/PAGE. C indi-
cates no enzyme control. The arrow indicates the position of a high
aﬃnity cleavage site.
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whereas the rate of DNA religation is dramatically
reduced in the presence of CPT (Figure 5B). In contrast,
the rate of DNA religation was substantially enhanced in
the case of the htop1Thr729Pro or htop1Thr729Lys. We
also tested the htop1Thr729Glu kinetic of religation using
the described suicide DNA substrate and other substrates
that diﬀer for length and nucleotide sequence. We were
unable to detect any cleavage of suicide DNA substrates in
the absence and in the presence of an annealed religation
strand. These data are consistent with a decrease in
mutant enzyme binding to DNA.
ThesubstitutionofThr729involvesamechanismofdecreased
DNA binding by DNA topoisomerase
The failure in the recognition of a suicide DNA substrate,
the absence of any trapped DNA cleaved products in the
presence of CPT and the reduced capability to relax
the DNA in physiologic ionic strength conditions by the
htop1Thr729Glu enzyme, are strictly related to one of
the steps involved in the catalytic cycle of the enzyme: the
equilibrium DNA binding/DNA dissociation. To address
this point, we analyzed the kinetics of DNA relaxation of
the three CPT-resistant mutants htop1Thr729Pro, htop1
Thr729Lys and htop1Thr729Glu, compared to that of the
wild-type enzyme. The experiments were conducted in the
presenceof150mMKCl,usingequalproteinamountswith
an excess or a deﬁcit of negatively supercoiled plasmid
DNA compared to the enzyme (DNA/enzyme ratio 3:1
or 1:3) (Figure 6). In the presence of excess DNA, all the
enzyme molecules are assumed to interact with the sub-
strate. Inthese conditions,thespeedoftherelaxation activ-
ity can be expressed as a function of the enzyme Km.A s
shown in Figure 6, both the htop1Thr729Lys and htop1
Thr729Glu enzymes relax the DNA more slowly than
wild-type accomplishing the same ﬁnal relaxation level.
In the presence of excess protein versus the DNA
substrate, hTopIp relaxes DNA in a processive manner.
Figure 5. Analysis of the religation rate using a suicide substrate. (A) In the oligonucleotide-based suicide substrate, cleavage of the 50-radiolabeled
scissile strand (14nt) liberates an AG dinucleotide to trap the covalent DNA–hTop1p complex. (B) The percentage of DNA relegation, in the
presence and in the absence of CPT, was determined by ImageQuant software and normalized to the total amount of radioactivity in each lane:
hTop1p (ﬁlled square), htop1Thr729Pro (ﬁlled traingle), htop1Thr729Lys.
Figure 6. Time course of plasmid DNA relaxation catalyzed by hTop1p, htop1Thr729Pro, htop1Thr729Lys and htop1Thr729Glu. Equal concentra-
tions of hTop1p, htop1Thr729Pro, htop1Thr729Lys and htop1Thr729Glu were incubated with supercoiled plasmid DNA in the presence of 150mM
KCl in the presence of an excess of DNA (A) or protein (B). At the times indicated, aliquots were treated with 0.5% SDS and the reaction products
were resolved in agarose gels as in Figure 2.
5640 Nucleic Acids Research, 2008, Vol. 36, No. 17The same eﬀect cannot be obtained in the case of the
Thr729Glu mutant, which continues to be distributive in
relaxing negatively supercoiled DNA.
These results suggest that the replacement of the Thr729
to Glu alters signiﬁcantly the tertiary structure of the
C-terminal hTop1p domain compromising the enzyme
aﬃnity to the DNA.
In order to quantify the diﬀerence in DNA binding by
the three obtained CPT-resistant enzymes, a ﬁlter binding
assay was performed. Increasing amounts of wild-type
enzyme and mutants were incubated with a 100-bp labeled
DNA fragment, Figure 7A, containing the speciﬁc
hTop1p recognition sequence as described in the
Material and methods section. The reaction mixtures
were applied to a nitrocellulose ﬁlter and the amount of
DNA retained was counted. Figure 7B shows the percent
of bound DNA as a function of the enzyme concentration.
As it can be appreciated, the amount of DNA bound by
the three mutant proteins was signiﬁcantly reduced rela-
tive to the wild-type. Coherently with the reduced catalytic
activity observed in the relaxation assays and in the DNA
cleavage assay, the DNA binding proﬁle obtained with the
single mutant htop1Thr729Lys and htop1Thr729Glu
proves that changes in the hydrophobic properties of the
C-terminal region of the enzyme radically aﬀect the DNA
binding/DNA dissociation equilibrium by hTop1p.
DISCUSSION
Mutations that impart resistance to CPT have been iden-
tiﬁed in several regions of human topoisomerase I. Few of
them involve residues making direct contacts with the
drug, many others cluster in the Lips region between the
CAP (subdomain I and II) and CAT (subdomain III and
C-terminal domain) regions. Some others are located in
the CAT domain (2,15,28). Some of these mutations alter
the enzyme catalytic cycle giving important clues on
enzyme activity.
The Thr729 to Ala substitution that has been isolated in
a CPT11 resistant tumor cell line (12) is located in the
C-terminal domain and its side chain forms a 2.6-A ˚ hydro-
gen bond with the hydroxyl group of Tyr619. This inter-
action stabilize the contacts between the C-terminal and
core subdomain III regions of the CAT, that extends from
the top half of the molecule downward by a couple of long
helices (8 and 9) functioning as an hinge that opens and
closes the enzyme around DNA. Thr729 and Tyr619 are
positioned respectively in a-helix 21 and a-helix 17 that
together with helix 16 constitute a hydrophobic pocket
(11). This three-helix structure bridges the linker, the
active site region and the hinge. In addition, as discussed
by Chrencik et al. (15), the Thr729 residue could have an
important role in the geometry of the enzyme C-terminal
region. In the X-ray structure, in fact, Thr729 forms a
water-mediated contact with the backbone carbonyl
oxygen atom of Asp725 and is positioned on the same
a-helix of the Asn 722 residue, which interacts with the
CPT through a water-mediated bond.
Our analyses of Thr729 mutations in human Top1p,
in vitro and in vivo, support this model but suggest that
the charge and geometry of amino acid side chains at this
position, directly impact the active site architecture and
the sensitivity of hTop1p to CPT.
Figure 7. DNA-binding assay. Increasing amounts of hTop1p, htop1Thr729Pro, htop1Thr729Lys and htop1Thr729Glu were incubated with an end-
labeled 100-nt double-strand DNA fragment as described in Materials and methods section. The percentage of DNA binding as a function of enzyme
concentrated is illustrated.
Nucleic Acids Research, 2008, Vol. 36, No. 17 5641Surprisingly the substitution Thr729Ala, when tested in
the S. cerevisiae yeast system, did not show any level of
drug resistance as in the tumor cell line.
Our results clearly indicate that the introduction of a
basic or an acidic side chain (Thr729Lys or Thr729Glu)
changes the quality of DNA binding, rendering in this
case the enzyme CPT resistant. In fact, the Thr729Glu
mutation completely abolish DNA binding, while the
Thr729Lys substitution can still bind to DNA but with a
reduced aﬃnity if compared to the wild-type enzyme.
In contrast, when the Thr729 was substituted by a
hydrophobic residue as Ala or Pro, the same eﬀect was
not observed. The Thr729Ala mutation shows CPT sensi-
tivity comparable to that of the wild-type without any
observable alterations in the speciﬁc catalytic activity,
both in the plasmid DNA relaxation and in cleavage/
religation assays.
The replacement of Thr729 by Pro, a residue that could
distort the a-helix, reduces the enzyme sensitivity to CPT
with a less extent than the two polar substitutions
Thr729Lys and Thr729Glu. Taken together, our data sup-
port the idea that changing the hydrophobic interactions
between helices 16, 17 and 21, by the addition of a charged
residue, must have a dramatic eﬀect in enzyme stability.
It has been previously demonstrated that topo58, a
C-terminal deletion of topo70, but comprising the core
subdomain III, is still able to bind DNA with the same
aﬃnity than the topo70 enzyme (29). It is quite surprising
that a single hydrophilic substitution in the C-terminal
may have such a dramatic eﬀect on DNA binding.
The results reported in the accompanying paper rein-
force our data showing a diﬀerent dynamic behavior for
the Thr729Pro and the Thr729Lys mutants, if compared
to the wild-type protein. In fact, while in the presence of
the Thr729Lys mutation some high ﬂuctuations in the
region comprising helices 16 and 17 has been observed,
the same region shows a reduction of mobility in the
Thr729Pro mutant.
Moreover, the evidence that CPT has little eﬀect on the
rate of DNA religation by Thr729Pro and Thr729Lys
mutants, suggests that their alterations in protein–DNA
interaction can also aﬀect drug binding to the covalent
complex.
As shown in Figure 8, panel C2, in the wild-type protein
a direct hydrogen bond between helix 21 and helix 17 is
formed by the Thr729 and Tyr619. The results obtained by
the dynamic simulation described in the accompanying
paper have shown that in the case of the Thr729Pro
mutant the direct hydrogen bond became lost without
altering the relative positions of the two helices
(Figure 8, panel D2). On the contrary, the Thr729Lys
mutation provokes a more dramatic eﬀect. As it can
be seen in Figure 8, panel B2, the loss of the direct
hydrogen bond is followed by the moving away of helix
21 from helix 17 with a direct eﬀect on the drug-binding
pocket.
Moreover the two mutations exert a diﬀerent eﬀect
on DNA religation as it can be seen in Figure 5. In fact,
while htopIThr729Lys shows an increase in the rate of
DNA religation in the absence of CPT, the activity of
htopIThr729Pro is comparable to that of the wild-type
enzyme in the same conditions. The addition of CPT
dramatically reduces the religation rate for the wild-type
protein, but does not show any eﬀect in the case of
htopIThr729Lys and a mild reduction for the
htop1Thr729Pro.
In addition, topIThr729Glu was unable to cleave any
suicide substrate used in our assays supporting the
hypothesis that the drug resistance is due to the reduced
DNA binding.
The kinetics of DNA relaxation in the presence of an
excess of substrate, displays a distributive mode of action
Figure 8. Structure modiﬁcations induced by the Thr729 mutations. Panel A1: helix 16, in core domain, and helix 21, in the C-terminal domain are
highlighted in red and light blue colours, respectively. Panel B1–C1–D1: only the helices are shown in representative snapshots of the
htopIThr729Lys, with hTopIp and htopIThr729Pro simulations, respectively. The side chains of Thr606 and Trp732, in helixes 16 and 17, respec-
tively, are shown in ball and stick. Stable direct hydrogen bonds, when present, are indicated with a white line. Panel A2: helix 17, in core domain,
and helices 20 and 21, in the C-terminal domain are highlighted in red and light blue colours, respectively. Panel B2–C2–D2: only the helices are
shown in representative snapshots of the htopIThr729Lys, hTopIp and htopIThr729Pro simulations, respectively. The side chains of Lys720, in helix
20, of the mutated residue 729, in helix 21, and of Tyr619, in helix 17 are shown in ball and stick. Stable direct hydrogen bonds, when present, are
indicated with a white line.
5642 Nucleic Acids Research, 2008, Vol. 36, No. 17both for htopIThr729Lys and htopIThr729Glu. The same
results cannot be observed in the presence of an excess of
protein. In these conditions, only htopIThr729Glu relaxed
DNA distributively while htopIThr729Lys restored its
processivity. This data are strongly supported by the
binding assay, where htop1Thr729Glu was unable to
bind the given substrate independently by the protein
concentration.
We previously demonstrated that the ﬂexibility of the
linker domain aﬀects the geometry of the active site inﬂu-
encing the DNA cleavage/religation equilibrium of the
enzyme and the CPT sensitivity through long-range con-
formational contacts (9,30).
In addition, a dynamic coupling between the linker
domain ﬂexibility and the active site of hTop1p may
also be inferred from X-ray structures of Topo70 in the
presence and the absence of the CPT analog TPT, where
the ﬂexibility of the linker domain prevents its structural
determination. However, in the ternary Topo70–DNA–
TPT complex, the structure of the linker domain could
be resolved (11).
A detailed comparison of the ternary structure of the
Topo70–DNA covalent complex in the presence and
absence of TPT shows that helix 16 is half a turn shorter
in the absence of the drug. In the presence of TPT Thr606
and Trp732, sited on the helices 16 and 21, respectively,
forms an hydrogen bond between Trp732 and Thr606
(Figure 8B) that is lost in the absence of the drug, where
Thr606 is positioned in the misfolded part of the helix 16.
The data described in the accompanying paper show that
this interaction is similarly lost in the htop1Thr729Lys
dynamic simulation (Figure 8, panels B1, C1 and D1)
where a partial destructuration of the helix 16, has been
observed.
It is interesting to observe that the linker domain is
directly connected to the hydrophobic pocket formed by
helices 16, 17 and 21 by two long ﬂexible loops that extend
from the two coiled-coil towards helix 17 directly and helix
21 via the catalytic Tyr region. This coordinated structure
could be strongly inﬂuenced by the radical change
imposed by the introduction of charged residues. The
dynamic cross-correlation map of the htop1Thr729Pro
and htop1Thr729Lys mutants compared to that of
the wild-type, described in the accompanying paper,
show a dramatic change in the protein dynamics.
In fact, while in the wild-type protein the linker and
the C-terminal domains move in an anticorrelated way,
the Thr729Lys mutation abolishes this motions and the
Thr729Pro provokes an increased rigidity in the same
domains.
Taken together, the experimental and the simulation
data indicate that a single change in a crucial residue
may alter dramatically the behavior of DNA topoisome-
rase IB, giving important clues on its dynamic mode of
action.
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